Steven Cohen’s Relay Therapeutics RLAY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-13,859,172
Closed -$117M 4377
2025
Q4
$117M Sell
13,859,172
-914,504
-6% -$6.53M 0.13% 145
2025
Q3
$77.1M Buy
14,773,676
+1,327,972
+10% +$5.06M 0.13% 177
2025
Q2
$46.5M Buy
13,445,704
+2,618,637
+24% +$7.79M 0.09% 261
2025
Q1
$28.4M Buy
10,827,067
+9,234,314
+580% +$36.2M 0.06% 353
2024
Q4
$6.56M Buy
1,592,753
+243,353
+18% +$1.32M 0.01% 860
2024
Q3
$9.55M Buy
+1,349,400
New +$10.1M 0.02% 660
2024
Q2
Sell
-952,019
Closed -$7.9M 2353
2024
Q1
$7.9M Buy
+952,019
New +$9.29M 0.02% 805
2023
Q4
Sell
-20,215
Closed -$170K 2711
2023
Q3
$170K Sell
20,215
-256,325
-93% -$2.76M ﹤0.01% 1805
2023
Q2
$3.47M Buy
+276,540
New +$3.44M 0.01% 927

Other funds holding RLAY

Steven Cohen's RLAY Position: Q1 2026 in Review

Steven Cohen sold out of Relay Therapeutics (RLAY) in Q1 2026, closing a stake of 13,859,172 shares — an estimated $117M sold.

Steven Cohen first reported a position in RLAY in Q2 2023 and held it in 9 quarters. The position peaked at $117M in Q4 2025. 243 funds tracked by Wall St. Rank hold RLAY as of Q1 2026.

  • Steven Cohen reported no remaining Relay Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Steven Cohen sold 13,859,172 Relay Therapeutics shares in Q1 2026, an estimated $117M.
  • Steven Cohen first reported a position in Relay Therapeutics in Q2 2023 and held it in 9 quarters.
  • Steven Cohen's Relay Therapeutics position peaked at $117M in Q4 2025.
  • 243 funds tracked by Wall St. Rank held Relay Therapeutics as of Q1 2026.

Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.